Hematologic Malignancies Therapeutics Market: Key Drivers Shaping Treatment Innovation
Valued at USD 71.38 billion in 2024, the hematologic malignancies therapeutics market is projected to reach USD 76.63 billion in 2025 and USD 148.15 billion by 2034, growing at a CAGR of 7.6% during the forecast period 2025–2034. Leading companies include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, Novartis...
